Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Wnt Pathway Modulator Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for TAX1BP3 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | TAX1BP3 Recombinant Protein (PDZ Domain / Full Length) High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. Suitable for FP and SPR binding assays. |
View TAX1BP3 Products |
| Gene Delivery | TAX1BP3 Promise-ORF / Lentivirus Full-length ORF for stable cell line generation to monitor Wnt pathway activity. |
View TAX1BP3 Products |
| Benchmark Ab | Anti-TAX1BP3 Recombinant Antibody Sequence-verified positive control for Western Blot and Immunoprecipitation. |
View TAX1BP3 Products |
| Validator | TAX1BP3 siRNA Set Target-specific knockdown verification in target-validation assays. |
View TAX1BP3 Products |
| Related Target A | CTNNB1 (β-catenin) Downstream signaling effector; TAX1BP3 acts as a key regulator of β-catenin transcriptional activity. |
View CTNNB1 Products |
| Related Target B | GIPC1 Homologous PDZ domain-containing protein; critical for off-target selectivity and counter-screening panels. |
View GIPC1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| PDZ Domain Off-Target Binding / Selectivity | Recombinant human TAX1BP3 and homologous GIPC1 proteins strictly verified by mass spectrometry and sequence analysis to ensure high-fidelity target screening. |
| Intracellular Target Validation | Validated siRNA sets and high-titer lentiviral particles designed for robust knockdown and stable overexpression in cancer cell lines. |
| Lack of Reliable Controls | Sequence-defined recombinant benchmark antibodies included to ensure reproducibility across assay batches. |
| Assay Artifacts / False Positives | High-purity (>95%), endotoxin-controlled preparations minimize non-specific interactions in biophysical assays (SPR, MST, FP). |
Live TAX1BP3 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for TAX1BP3 therapeutics is intensifying, with major players shifting focus from traditional scaffold exploration to targeted protein-protein interaction (PPI) disruptors and targeted protein degradation (PROTACs). As first-generation small-molecule inhibitors targeting the single PDZ domain of TAX1BP3 reach preclinical and early clinical validation, the next wave of R&D is targeting synergistic combinations with canonical Wnt inhibitors to overcome resistance in colorectal cancer and glioblastoma.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule / Peptidomimetic | Academic Consortia, Biotech Startups | Glioblastoma, Colorectal Cancer | Biophysical binding assays (FP/SPR) requiring high-purity, natively folded PDZ domain proteins. |
| PROTAC / Degrader | Oncology-focused Biopharma | Refractory Solid Tumors | Ternary complex validation assays requiring biotinylated or tagged TAX1BP3 target proteins. |
| Gene Therapy / RNAi | RNA Therapeutics Specialists | Metastatic Cancer | In vitro validation using sequence-verified siRNA knockdown and lentiviral rescue lines. |